Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

Results % Growth ------------------ ------- --------- Earnings (Loss) per share ($1.56) to ($2.06) $2.71 (reported) Estimated financial impact of ImClone acquisition, including in-process research and development and other charges 4.05 to 4.50 - Charges related to Zyprexa investigations 1.33 - Asset impairments and restructuring charges (included in asset impairments, restructuring and other special charges) .25 .15 Asset impairments (included in cost of sales) .04 - In-process research and development charges associated with SGX acquisition (2008), ICOS, Hypnion, and Ivy acquisitions (2007) and in-licensing transactions with BioMS and TransPharma (2008) and OSI, MacroGenics and Glenmark (2007) .10 .63 Benefit from resolution of IRS audit (.19) - Charge for a reduction in expected insurance recoveries - .06 Pro forma as if the ICOS acquisition was completed on January 1, 2007 - (.01) -------------- --------- Earnings per share (pro forma non-GAAP) $3.97 to $4.02 $3.54 12% to 14% -------------- ---------

2009 Financial Guidance

In 2009, the company expects earnings per share of $4.00 to $4.25 on both a reported and non-GAAP basis. Excluding the estimated dilution impact of $0.30 to $0.35 per share related to the ImClone acquisition, earnings per share would be expected to be in the range of $4.35 to $4.55, reflecting growth of 8 percent to 15 percent compared to 2008 non-
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... control projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... volume year for bidding in 2014, we are pleased to see ... reflect the organization,s renewed focus on select market segments where we ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... has closed a public offering of three million ... million for general corporate purposes. , ,The company announced ... $3.75 per share, marketed to institutional investors following a ... Exchange Commission . , ,Sonic Foundry, which develops a ...
... , a Grand Rapids-based provider of data bandwidth capacity, will ... in metropolitan Milwaukee. , ,The company, which serves Midwestern enterprise ... 31 of this year. , ,US Signal's network deployment ... Milwaukee and powered by the Cisco optical platform. ...
... Madison, Wis. - Third Wave Technologies, Inc ., ... to the U.S. Food and Drug Administration for approval of ... test product, which Third Wave calls InPlex, is a genotyping ... to aid in newborn screening and in diagnostic testing in ...
Cached Biology Technology:
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... of choice when it comes to the types of fat cells in ... it. The danger in white fat cells, along with the increased risk ... fat. Visceral fat is the build-up of fat around the organs in ... fat appears to be our friend and white fat our foe. ...
... FL (May 6, 2012) There may be new ... medicine injected directly into the eyes fails to cause ... called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle ... with the fast-progressive form of macular degeneration, they are ...
... in German . Halle/Saale. In order to ... These differ in part considerably from the propagation strategies of ... Knapp of the Helmholtz Centre for Environmental Research (UFZ) reached ... of the scientific journal Ecology Letters . "These results ...
Cached Biology News:A new candidate pathway for treating visceral obesity 2First oral agent to quell invasive macular degeneration, restore lost vision 2First oral agent to quell invasive macular degeneration, restore lost vision 3Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: